[1] 李冰,郑秋红.DC-CIK细胞联合化疗治疗晚期非小细胞肺癌的临床探讨[J].黑龙江医学,2011,35(1):4-7.
[2] FEHRENBACHER L,SPIRA A,BALLINGER M,et al.Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR):a multicentre,open-label,phase 2 randomised controlled trial[J].Lancet,2016,387(10030):1837-1846.
[3] NAIDOO J,SCHINDLER K,QUERFELD C,et al.Autoimmune Bullous skin disorders with immune checkpoint inhibitors targeting PD-1 and PD-L1[J].Cancer Immunol Res,2016,4(5):383-389.
[4] GAUTSCHI O,MILIA J,CABARROU B,et al.Targeted Therapy for Patients with BRAF-Mutant Lung Cancer:Results from the European EURAF Cohort[J].J Thorac Oncol,2015,10:1451-1457.
[5] 闫相涛,王慧娟,李鹏,等.免疫治疗后进展的晚期非小细胞肺癌二线继续免疫治疗联合化疗的回顾性分析[J].肿瘤学杂志,2021,27(3):186-190.
[6] MAZIERES J,ZALCMAN G,CRINO L,et al.Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement:results from the EUROS1 cohort[J].J Clin Oncol,2015,33:992-999.
[7] MAZIERES J,BARLESI F,FILLERON T,et al.Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs:results from the European EUHER2 cohort[J].Ann Oncol,2016,27:281-286.
[8] VOKES N I,CHAMBERS E,NGUYEN T,et al.Concurrent TP53 mutations facilitate resistance evolution in EGFR-mutant lung adenocarcinoma[J].J Thorac Oncol,2022,17(6):779-792.
[9] FUNG A S,KARIMI M,MICHIELS S,et al.Prognostic and predictive effect of KRAS gene copy number and mutation status in early stage non-small cell lung cancer patients[J].Transl Lung Cancer Res,2021,10(2):826-838.
[10] 陈家祯,王玉,王存良,等.晚期非小细胞肺癌PD-1单抗治疗疗效的临床影响因素分析[J].中华转移性肿瘤杂志,2022,5(2):109-115.
[11] CHEN N,FANG W,LIN Z,et al.KRAS mutation-induced upregulation of PD-L1 mediates immune escape in human lung adenocarcinoma[J].Cancer Immunol Immunother,2017,66(9):1175-1187.
[12] HEIDORN S J,MIAGRE C,WHITTAKER S,et al.Kinase-dead BRAF and oncogenic RAS cooperate to drive tumorprogression through CRAF[J].Cell,2010,140(2):209-221.
[13] 黎文锋. TP53基因对EGFR突变晚期非小细胞癌患者的预测和预后意义[D].广州:华南理工大学,2021.
[14] DUDNIK E,PELED N,NECHUSHTAN H,et al.BRAF mutant lung cancer:programmed death ligand 1 expression,tumor mutational burden,microsatellite instability status,and response to immune check-point inhibitors[J].J Thorac Oncol,2018,13(8):1128-1137.
[15] SABARI J K,LEONARDI G C,SHU C A,et al.PD-L1 expression,tumor mutational burden,and response to immunotherapy in patients with MET exon 14 altered lung cancers[J].Ann Oncol,2018,29(10):2085-2091.
[16] TAYLOR AB,WILLA SB,ELIZABETH AV,et al.Expansion of the phenotypic spectrum of KARS1‐related disorders to include arthrogryposis multiplex congenita and summary of experiences with lysine supplementation[J].American journal of medical genetics,Part A,2024,194A(11):e63811. |
